Placebo
Dietary SupplementA mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
NCT Number: NCT04148976
The primary aim of the present study was to elucidate the effect of a combination of functional foods on the low-density lipoprotein cholesterol (LDL-C) levels and on the distribution of the lipoprotein subclasses in subjects with hypercholesterolemia. To accomplish the latter, subjects that met the inclusion criteria and had mild hypercholesterolemia (Total cholesterol >200mg/dL, and LDL-C >130mg/dL <190 mg/dL) were recruited for double-blind, parallel, controlled dietary intervention study. After two weeks of dietary standardization with an isocaloric diet, subjects were randomized and allocated to either placebo or a dietary portfolio treatment for two months. The secondary endpoints were the size of the different lipoprotein subclasses, total cholesterol levels, high density -lipoprotein cholesterol (HDL-C) levels, apolipoprotein B, triglycerides, total/HDL-C ratio, apolipoprotein B/apolipoprotein A ratio, and anthropometric measurements.
Looking for future studies?
Notify Me20 year–60 year
All sexes
Interventional
Not applicable
The present work took place at the Department of Physiology of Nutrition at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ). The study followed a randomized, controlled, double-blind, parallel design encompassing five visits. On the first visit, volunteers were screened for eligibility criteria. Subjects that met the inclusion criteria were then invited to a second visit. Herein, volunteers received a thorough explanation of the experimental maneuver, as well as the overall objectives of the study. Thereafter, subjects who agreed to participate signed a consent form.
Upon agreement, assessment of habitual dietary intake and physical activity was obtained by 24-hour dietary recalls, food frequency questionnaire (FFQ), and by the International Physical Activity Questionnaire (IPAQ), respectively. Additionally, anthropometric measurements and blood samples were registered and collected. Then, volunteers underwent dietary standardization for two weeks with isocaloric diets (LSFD), which followed the National Cholesterol Education Program (NCEP) , Adult Treatment Panel III (ATP III) criteria. That is, 50-60% carbohydrates, 15% protein, 25-35% fat,<7% saturated fat,≤ 200mg of dietary cholesterol, 20-35g of fiber, and 2000mg/d of sodium.
On the third visit, subjects were randomly allocated to either LSFD plus placebo or an LSFD plus the dietary portfolio (DP). Of note, the prescribed diets were matched to the volunteers' habitual caloric intake -considering the energy provided by the placebo or DP- to avoid variability of the endpoint variables due to weight-loss. The DP and placebo provided 200kcal; the DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The organoleptic characteristics and packaging were similar between treatments. Subjects were instructed to consume two packets per day, preferably with breakfast and dinner. The content of each packet (30g of product) was dissolved in 250-300ml of water.
Volunteers followed the given treatment for two consecutive months, during which two follow-up visits took place. Blood samples, anthropometric characteristics, and blood pressure were obtained in all visits.
Compliance to diet, placebo, and DP was assessed with 24-hour dietary recalls, 3-day dietary records, and with the number of empty packets returned on the corresponding visits.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Antihypertensive drugs Hypoglycemic agents Statins, fibrates or any other treatment for dyslipidemia Steroid medications Chemotherapy, immunosuppressants, and radiotherapy Anorexigens or other medication to induce weight-loss
A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
A mixture of functional foods divided into 30g individual packets.
Time frame: Change in total LDL-C after 2.5 months of treatment
Plasma total LDL-C (mg/dl)
Time frame: Change in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatment
High density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) subclasses (small medium and large) as measure by nuclear magnetic resonance spectroscopy (NMR) in μmol/L.
Time frame: Change in total cholesterol after 2.5 months of treatment
Plasma total cholesterol (mg/dL)
Time frame: Change in triglycerides after 2.5 months of treatment
Plasma triglycerides (mg/dL)
Time frame: Change after 2.5 months of treatment
Plasma HDL cholesterol (mg/dL)
Time frame: Change after 2.5 months of treatment
Change in apolipoprotein B in
Time frame: Change after 2.5 months of treatment
Change in apolipoprotein A in plasma
Time frame: Change after 2.5 months of treatment
Change in total/ high density lipoprotein cholesterol (HDL-C) ratio
Time frame: Change after 2.5 months of treatment
Change in Apolipoprotein B / Apolipoprotein A ratio
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Other
Effect of Dietary Intervention on LDL-C Levels and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05988866
Dyslipidemias, Hypercholesterolemia
Hamburg, Germany
View Trial DetailsNCT07175766
Cardiovascular Diseases, Dyslipidemias
Taoyuan, Taiwan
View Trial DetailsNCT06005597
ASCVD, Arterial Occlusive Diseases
Gilbert, Arizona, United States
View Trial DetailsNCT05142722
Arterial Occlusive Diseases, Arteriosclerosis
Anniston, Alabama, United States
View Trial Details